presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

presentation1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.pptx by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image3_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image1_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image3_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

image2_Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways.tif by Xin Zhi (1829224)

“…Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. …”

AIF1L regulates actomyosin contractility and filopodial extensions in human podocytes by Mako Yasuda-Yamahara (5509151)

“…Genetic deletion of <i>AIF1L</i> in immortalized human podocytes resulted in an increased formation of filopodial extensions and decreased actomyosin contractility. By the use of SILAC based quantitative proteomics analysis we describe the podocyte specific AIF1L interactome and identify several components of the actomyosin machinery such as MYL9 and UNC45A as potential AIF1L interaction partners. …”

Can stochasticity reverse selection? Here we compare two models of altruism having the same per-capita growth rate, but differing in variance in per-capita growth (Model 1-red, Mod... by David V. McLeod (6293807)

BQSR recalibration inaccuracies due to limited size and coverage of the ERCC spike-in standards, compared to the inaccuracies caused by recalibrating from the genome excluding know... by Justin M. Zook (146772)

Influence of Jet Fuel Composition on Aircraft Engine Emissions: A Synthesis of Aerosol Emissions Data from the NASA APEX, AAFEX, and ACCESS Missions by Richard H. Moore (544504)

“…Linear regression coefficients are reported for each aerosol EI in terms of these properties, engine fuel flow rate, and ambient temperature and show that reducing both fuel sulfur content and naphthalenes to near-zero levels would result in roughly a 10-fold decrease in aerosol number emitted per kilogram of fuel burned. …”

How much should we trust <i>R</i>² and adjusted <i>R</i>²: evidence from regressions in top economics journals and Monte Carlo simulations by Qiang Chen (114038)

“…<p>R² and adjusted R² may exaggerate a model’s true ability to predict the dependent variable in the presence of overfitting, whereas leave-one-out R² (LOOR²) is robust to overfitting. …”

Histogram of dorsum PROM divided into classifications and measured with an electrogoniometer. by Mark P. Wilhelm (9258177)

Curvature-Specific Coupling Electrode Design for a Stretchable Three-Dimensional Inorganic Piezoelectric Nanogenerator by Junwoo Yea (17041741)

“…When strains with opposite directions simultaneously affect piezoelectric materials, the electric output can decrease due to cancellation. Here, we report an electrode design tailored to the direction of strain and a circuit configuration that prevents electric output cancellation. …”

Curvature-Specific Coupling Electrode Design for a Stretchable Three-Dimensional Inorganic Piezoelectric Nanogenerator by Junwoo Yea (17041741)

“…When strains with opposite directions simultaneously affect piezoelectric materials, the electric output can decrease due to cancellation. Here, we report an electrode design tailored to the direction of strain and a circuit configuration that prevents electric output cancellation. …”

Exposure to a stressor activates the hypothalamic-pituitary-adrenal axis and sympathetic nervous system resulting in changes to the commensal flora (including a decrease in prevote... by Thomas Maslanik (295204)

Dosing analysis of the YFV vaccine (subcutaneous route) in interferon-1 receptor knockout mice (A129). by Ana C. Vicente Santos (11649118)

The effects of clonidine on mean arterial blood pressure, fluid flux and luminal alkalinisation. by Olof Nylander (599995)

“…<p>Duodenum was perfused with isotonic saline for 90 min and clonidine was administered from 30 min as a constant i.v. infusion at a dose of 10 or 50 μg kg^-1 h^-1 (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0273208#pone.0273208.g001" target="_blank">Fig 1</a>). …”